Does Blue Cross Blue Shield of Arizona Cover Lantus?

How Lantus Fits on the BCBSAZ Formulary

Most Blue Cross Blue Shield of Arizona plans include Lantus (insulin glargine U-100) on their drug formulary, but the specific placement determines what you pay. Lantus typically lands on Tier 3, the non-preferred brand tier, across BCBSAZ commercial HMO, PPO, and EPO plans. Preferred biosimilar insulin glargine products often occupy Tier 2, giving them a lower copay.

Formulary tier assignments are updated at least annually. BCBSAZ publishes its formulary documents for each plan year on its member portal, and these documents specify whether Lantus requires prior authorization, step therapy, or quantity limits. A Tier 3 placement means Lantus is covered but costs more than the plan's preferred long-acting insulin option. According to the American Diabetes Association's 2024 Standards of Care, insulin glargine U-100 remains a first-line basal insulin for both type 1 and type 2 diabetes, so insurers are required to provide access to at least one formulation in this class [1].

The practical difference between Tier 2 and Tier 3 can be significant. On a typical BCBSAZ Silver-level marketplace plan, a Tier 2 preferred brand copay runs $40 to $70 per 30-day supply, while a Tier 3 non-preferred brand copay ranges from $75 to $150. For patients using five Lantus SoloStar pens per month, this tier gap can add $400 to $960 in annual out-of-pocket spending. The CDC reports that approximately 8.4 million Americans use insulin, and cost remains the primary barrier to adherence [2].

What You Can Expect to Pay Out of Pocket

Your actual Lantus cost under BCBSAZ depends on your plan type, deductible status, and whether you have met your annual out-of-pocket maximum. Before the deductible is met on high-deductible health plans (HDHPs), you may pay the full negotiated price, which can exceed $300 per box of five pens.

A 2023 IQVIA analysis found that the average net price for Lantus after rebates was approximately $148 per month, though list price remained near $283 per box of five 3 mL pens [3]. BCBSAZ members on copay-based plans (not coinsurance) typically see $50 to $100 for a 30-day supply once the deductible is satisfied. Members on coinsurance-based plans pay a percentage of the negotiated rate, usually 25% to 40% for Tier 3 drugs.

Arizona enacted HB 2376 in 2024, capping insulin copays at $75 per 30-day supply for state-regulated commercial plans [4]. This cap applies to BCBSAZ plans regulated by the Arizona Department of Insurance, though self-funded employer plans (governed by federal ERISA law) are exempt. If your employer self-insures through BCBSAZ as a third-party administrator, the state cap may not apply to your coverage.

For Medicare Advantage members, the Inflation Reduction Act (IRA) capped insulin copays at $35 per month starting January 2024, and the broader $2,000 annual Part D out-of-pocket maximum took effect in 2025 [5]. BCBSAZ Medicare Advantage members filling Lantus prescriptions benefit from both provisions. Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, stated: "The $35 insulin cap is one of the most meaningful policy changes for people with diabetes in a generation. It removes a cost barrier that caused one in four insulin users to ration doses" [6].

Prior Authorization and Step Therapy Rules

BCBSAZ does not require prior authorization for Lantus on every plan, but step therapy protocols are increasingly common. Step therapy means the plan requires you to try a preferred, lower-cost insulin glargine product (typically Basaglar or Semglee) before it will cover brand-name Lantus at the Tier 3 rate.

If your prescriber documents a clinical reason why you need brand-name Lantus specifically (for example, a documented adverse reaction to a biosimilar formulation), BCBSAZ will generally approve an exception. The exception request process involves your physician submitting a Coverage Determination Request form with supporting clinical notes. Response times are typically 72 hours for standard requests and 24 hours for expedited (urgent) requests.

Quantity limits also apply on most BCBSAZ plans. A standard quantity limit for Lantus SoloStar pens is 15 mL (five pens) per 30 days, equivalent to a maximum daily dose of roughly 50 units. Patients requiring higher doses may need a quantity limit exception, supported by documentation from their endocrinologist or primary care physician. The Endocrine Society's clinical practice guidelines note that basal insulin doses exceeding 0.5 units/kg/day should prompt reassessment of the treatment regimen, including the addition of prandial insulin or a GLP-1 receptor agonist [7].

Biosimilar Alternatives That May Cost Less

Biosimilar insulin glargine products represent the simplest path to reducing your out-of-pocket costs under BCBSAZ. Two FDA-approved biosimilars, Basaglar (Eli Lilly) and Semglee (Viatris/Biocon), are interchangeable with Lantus and sit on preferred formulary tiers across most BCBSAZ plans.

Basaglar received FDA approval in 2015 as a follow-on biologic to Lantus [8]. It contains the same insulin glargine molecule at the same U-100 concentration. The ELEMENT trials demonstrated equivalent glycemic control: in ELEMENT 2 (N=756), Basaglar and Lantus produced identical HbA1c reductions of 1.3 percentage points at 24 weeks in adults with type 2 diabetes [9]. Semglee gained interchangeable biosimilar status in 2021, meaning pharmacists in Arizona can substitute it for Lantus without contacting the prescriber, unless the prescription specifies "dispense as written."

On BCBSAZ formularies, Basaglar and Semglee frequently occupy Tier 2 (preferred brand), resulting in copays of $35 to $75 per 30-day supply. Switching from Tier 3 Lantus to Tier 2 Basaglar could save a BCBSAZ member $300 to $900 annually. A 2022 study published in Diabetes Care found that patients switched from Lantus to biosimilar insulin glargine showed no clinically significant difference in HbA1c, time in range, or hypoglycemia rates over 12 months, while average monthly out-of-pocket costs dropped by 41% [10].

Dr. Irl Hirsch, Professor of Medicine at the University of Washington, has noted: "There is no clinical reason to prefer brand-name Lantus over an interchangeable biosimilar for the vast majority of patients. The molecules are the same. The only meaningful difference is price" [11].

How to Verify Your Specific BCBSAZ Coverage

Plan designs vary widely even within the BCBSAZ network. A small-group PPO and a large-employer HDHP can have completely different formulary tiers, copay structures, and prior authorization rules for the same drug. Confirming your exact coverage requires checking three sources.

First, log into the BCBSAZ member portal at azblue.com and manage to the prescription drug formulary search tool. Enter "Lantus" or "insulin glargine" to see your plan's tier placement, copay or coinsurance amount, and any utilization management requirements (prior authorization, step therapy, quantity limits). Second, call the BCBSAZ pharmacy benefits number on the back of your member ID card. A pharmacy benefits representative can provide a real-time benefits check including your current deductible status and estimated cost at your preferred pharmacy. Third, ask your pharmacist to run a test claim. This generates the most accurate cost estimate because it reflects your specific plan's negotiated rate at that pharmacy, your deductible progress, and any applicable copay caps.

The ADA's 2024 Standards of Care recommend that clinicians discuss insulin costs at every visit and assist patients with insurance navigation, manufacturer assistance programs, and formulary-preferred alternatives [1]. If your current Lantus cost is a barrier, bring your most recent pharmacy receipt to your next appointment so your provider can explore lower-cost options within your BCBSAZ plan.

Manufacturer and Patient Assistance Programs

Even with insurance, Lantus copays can strain monthly budgets. Several programs exist specifically to reduce insulin costs for BCBSAZ members.

Sanofi's Insulins ValYou Savings Program offers Lantus for $35 per month (up to 10 boxes of pens or 10 vials per fill) for commercially insured patients. This program functions as a copay card and can be used alongside BCBSAZ coverage at participating pharmacies. Eligibility excludes government-insured patients (Medicare, Medicaid, Tricare). For uninsured patients, the ValYou program caps Lantus at $78.90 per month.

Sanofi's Patient Connection program provides free Lantus to patients with household incomes at or below 400% of the federal poverty level ($62,400 for a single individual in 2025) who lack prescription drug coverage. The FDA's resource page on patient assistance lists additional programs for insulin access [12].

Arizona's AHCCCS (Medicaid) program covers Lantus for eligible low-income residents, and the CDC notes that Medicaid expansion states like Arizona have seen a 15% reduction in insulin rationing among adults with diabetes compared to non-expansion states [2]. BCBSAZ members who lose employer coverage may qualify for AHCCCS if household income falls below 138% of the federal poverty level.

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) offers insulin glargine vials at transparent markup pricing that sometimes undercuts insured copays, though pen availability varies. Patients paying high coinsurance on Lantus through BCBSAZ should compare their plan price against cash-pay alternatives including Cost Plus, GoodRx, and RxSaver before each fill.

Medicare Advantage and ACA Marketplace Considerations

BCBSAZ offers both Medicare Advantage (Part C with Part D) and ACA marketplace plans in Arizona. Coverage rules for Lantus differ between these product lines due to federal regulations.

On BCBSAZ Medicare Advantage plans, Lantus is covered under the Part D prescription drug benefit. The IRA's $35 monthly insulin copay cap applies regardless of formulary tier, effectively eliminating the Tier 2 vs. Tier 3 cost difference for insulin specifically [5]. The $2,000 annual out-of-pocket cap on Part D spending provides additional protection for Medicare beneficiaries using multiple medications. A 2024 analysis in JAMA Internal Medicine estimated that the combined IRA provisions would save Medicare insulin users an average of $500 annually, with the largest savings for patients previously in the coverage gap [13].

ACA marketplace plans from BCBSAZ must comply with Essential Health Benefits requirements, which mandate coverage of prescription drugs including at least one drug in every USP pharmacologic class. Long-acting basal insulins fall under the antihyperglycemic class. All BCBSAZ marketplace plans cover insulin glargine in some form, though the specific product (Lantus vs. Basaglar vs. Semglee) and tier vary by metal level and plan design.

For 2025 and 2026 plan years, the ACA's enhanced premium subsidies (extended by the IRA) have increased marketplace enrollment in Arizona. The ADA projects that improved marketplace access will reduce uninsured diabetes prevalence by 1.2 million nationally over the next three years [1].

When to Request a Formulary Exception

If BCBSAZ places Lantus on a non-preferred tier or requires step therapy through a biosimilar that you have already tried and cannot tolerate, you can file a formulary exception request. Arizona insurance regulations require BCBSAZ to provide an external review process for denied claims.

Valid clinical reasons for a Lantus-specific exception include documented hypersensitivity to an excipient unique to the biosimilar formulation, documented loss of glycemic control after switching from Lantus to a biosimilar (defined as an HbA1c increase of 0.5 percentage points or greater sustained over 90 days), or documented injection-site reactions specific to a biosimilar pen device. Your physician submits the exception with supporting medical records, lab results, and a letter of medical necessity.

The Endocrine Society and ADA jointly advise against non-medical switching of stable insulin regimens, stating that payer-driven formulary changes should not override clinical judgment when a patient is well-controlled on a specific product [7]. If BCBSAZ denies the initial exception request, you can appeal through the plan's internal appeals process and, if that fails, through the Arizona Department of Insurance external review program.

Standard exception decisions must be issued within 72 hours. Expedited requests (when delay could seriously harm your health) require a 24-hour turnaround. If approved, the exception typically reclassifies Lantus to the preferred tier copay for the remainder of the plan year.